ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1501

Assessment of Treatment Response Using the Multi-Biomarker Disease Activity Score in Rheumatoid Arthritis Patients Initiating Methotrexate

Tate Johnson1, Bryant R. England2, Harlan Sayles1, Geoffrey M. Thiele1, Ted R. Mikuls3 and James R. O'Dell4, 1University of Nebraska Medical Center, Omaha, NE, 2Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, 3Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 4Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: biomarkers and rheumatoid arthritis (RA), Disease Activity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The Multi-Biomarker Disease Activity (MBDA) score was developed to provide an objective measure of rheumatoid arthritis (RA) disease activity. Demonstrating moderate correlations with conventional measures of RA disease activity, the capacity of the MBDA to predict treatment response may vary among available disease-modifying agents. The performance of the MBDA in patients initiating methotrexate (MTX), a cornerstone therapy in RA, has not been evaluated to date.

Methods: We conducted a secondary analysis of a 16-week, open-label study of RA patients initiating MTX (15mg/wk) with dose escalation to 20mg/wk for those failing to achieve disease remission (DAS28 <2.6) at 8 weeks. The primary study outcome was the proportion achieving ACR50 response at week 16. MBDA scores were measured using banked serum collected at baseline (N=130) and week 16 (N=95). The association of baseline MBDA with treatment response was assessed using multivariable regression models adjusting for age, sex, race, smoking status, and rheumatoid factor (RF) concentration. Convergent validity and responsiveness were determined by calculating correlations of the MBDA with DAS28-ESR, ESR, patient global assessment (PtGA), Health Assessment Questionnaire (HAQ), as well as correlations of MBDA change with changes in alternative disease activity measures and through the calculation of standardized response means (SRM).

Results: Patients had a mean age of 54 yrs and were predominantly female (75%), seropositive (73% for RF, 75% for anti-CCP), and had high baseline disease activity (DAS28-ESR of 5.3, SD 1.2). Mean baseline MBDA score was 48.3 (SD 17.2) with 12%, 28%, and 61% categorized as low, moderate, and high disease activity by MBDA. After 16 weeks, the MBDA improved by a mean of 9.4 (SD 14.5) and DAS28-ESR improved by a mean of 1.9 (SD 1.5). Patients achieving an ACR50 response demonstrated greater reductions in MBDA than those failing to achieve an ACR50 response (p=0.01). However, baseline MBDA scores (OR 1.01, 95% CI 0.99, 1.04) and categories (moderate: OR 1.55, 95% CI 0.45-14.20; high: OR 2.55, 95% CI 0.50-12.98) were not predictive of response. Higher baseline MBDA scores were associated with greater improvement in DAS28-ESR (p=0.01), as were baseline DAS28-ESR values (p<0.001). The MBDA demonstrated moderate correlations with DAS28-ESR and ESR, but weaker correlations with the HAQ and PtGA (Table 1). Treatment responsiveness was greater for DAS28-ESR (SRM -1.32) than MBDA (SRM -0.65).

Conclusion: In this 16-week open-label study of MTX in RA patients, baseline MBDA was associated with greater reductions in DAS28-ESR but was not a robust predictor of ACR50 response. Although demonstrating moderate convergent validity with standard disease activity assessments, the MBDA yielded lower responsiveness than the DAS28-ESR in the context of MTX treatment.

Table 1. Correlation (r) of the MBDA Score with disease activity measures and functional status in RA patients initiating MTX

DAS28-ESR

ESR

PtGA

HAQ

r

p-value

r

p-value

r

p-value

r

p-value

MBDA

Baseline

Week 16

0.44

0.30

<0.001

0.004

0.59

0.51

<0.001

<0.001

0.23

0.19

0.008

0.07

0.34

0.23

<0.001

0.03

∆ DAS28-ESR

∆ ESR

∆ PtGA

∆ HAQ

∆ MBDA

0.42

<0.001

0.46

<0.001

0.23

0.02

0.25

0.02

Abbreviations: MBDA, Multi-Biomarker Disease Activity Score; ESR, erythrocyte sedimentation rate; PtGA, patient global assessment; HAQ, Health Assessment Questionnaire


Disclosure: T. Johnson, None; B. R. England, None; H. Sayles, None; G. M. Thiele, None; T. R. Mikuls, BMS, Ironwood, Horizon, 2,Pfizer, Inc., 5; J. R. O'Dell, Medac, 5.

To cite this abstract in AMA style:

Johnson T, England BR, Sayles H, Thiele GM, Mikuls TR, O'Dell JR. Assessment of Treatment Response Using the Multi-Biomarker Disease Activity Score in Rheumatoid Arthritis Patients Initiating Methotrexate [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/assessment-of-treatment-response-using-the-multi-biomarker-disease-activity-score-in-rheumatoid-arthritis-patients-initiating-methotrexate/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-treatment-response-using-the-multi-biomarker-disease-activity-score-in-rheumatoid-arthritis-patients-initiating-methotrexate/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology